Abstract: Poster Presentations |


Gregory B. Diette, MD*; Cynthia Rand, PhD; Katherine Thompson, RN; Andrew Bilderback, MA; Nadia N. Hansel, MD; Diane L. Kachel, BA; Brian Becker, M Ed; Robert A. Wise, MD
Author and Funding Information

Johns Hopkins University, Baltimore, MD


Chest. 2007;132(4_MeetingAbstracts):531a. doi:10.1378/chest.132.4_MeetingAbstracts.531a
Text Size: A A A
Published online


PURPOSE: Chronic mucous hypersecretion is common in moderate-severe COPD and is associated with respiratory infections and AE-COPD. HFCWO is accomplished using a pneumatic vest to facilitate mucous clearance. We hypothesized that patients using HFCWO therapy would have fewer AE-COPD.

METHODS: We conducted a sham-controlled, double-masked parallel group trial (N=50) of HFCWO (30 minutes daily for 12 weeks). Subjects had doctor diagnosed COPD, FEV1/FVC ≤; 70%, ≥ 20 pk-yrs tobacco, age ≥ 45yrs, daily mucous production, ≥ 1 AE-COPD in past 6 mos. The primary outcome was rate of AE-COPD, (modified Winnipeg criteria assessed by weekly interview).

RESULTS: Subjects wer64% male, 80% white and means age 63 years. 26 received active HFCWO (A) and 24 received a sham device (S). AE-COPD were common during the12-week follow-up (92% A vs. 95% S, p=.65). The rate of AE-COPD was lower in A than S ( 4 vs. 5.5/12wks, p<.02 by Poisson regression). By 12-weeks, the % of subjects with daily phlegm production decreased in A (75 to 52%), but increased in S (54 to 67%)(p=.35 for difference). Coughing up phlegm was more likely to become easy or mild in A than S (29 vs. 20%, p=.71). Quality of life (St. George's) improved in both S (p=.02) and A (p=.04), though there were no significant differences between groups (−6 vs. −3, p=.38). Self-reported adherence (daily use) was somewhat lower for A than S (57 vs. 80 %, p=.28).

CONCLUSION: This pilot study of active HFCWO therapy showed a significant reduction in the rate of AE-COPD compared with use of a sham device. Although no significant differences were found for symptoms and quality of life, the direction of change suggests a potential treatment effect.

CLINICAL IMPLICATIONS: HFCWO is a promising therapy to prevent AE-COPD. A larger and/or longer trial is needed to confirm the efficacy of HFCWO to prevent AE-COPD.

DISCLOSURE: Gregory Diette, No Product/Research Disclosure Information; University grant monies none; Grant monies (from sources other than industry) The Centers for Medicare and Medicaid Services provided grant support for this study; Grant monies (from industry related sources) Hill-Rom, Inc. provided financial support for this study.; Shareholder n/a; Employee n/a; Fiduciary position (of any organization, association, society, etc, other than ACCP n/a; Consultant fee, speaker bureau, advisory committee, etc. none; Other none

Wednesday, October 24, 2007

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543